NCCN Receives $2.2 Million in Research Funding From Astellas and Medivation to Study Enzalutamide in Solid Tumors

NCCN Receives $2.2 Million in Research Funding From Astellas and Medivation to 
Study Enzalutamide in Solid Tumors 
The NCCN Oncology Research Program (ORP) Received a $2.2-Million
Grant From Astellas Pharma, Inc. and Medivation, Inc. to Facilitate
Studies of Enzalutamide in Bladder, Breast, Endometrial,
Hepatocellular, Ovarian, and Prostate Cancers 
FORT WASHINGTON, PA  -- (Marketwired) -- 03/31/14 --  The National
Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP)
has been awarded a $2.2-million grant from Astellas Pharma, Inc. and
Medivation, Inc. to develop a program to scientifically evaluate and
define the clinical effectiveness of enzalutamide in solid tumors,
including bladder, breast, endometrial, hepatocellular, ovarian, and
prostate cancers. 
"This grant from Astellas and Medivation gives investigators at NCCN
Member Institutions a remarkable opportunity to study the
effectiveness of enzalutamide in six cancer types," said Diane E.
Paul, MS, RN, Vice President, NCCN ORP. "NCCN is grateful to
collaborate with Astellas and Medivation on this research initiative
that has the potential to positively affect the treatment of people
with cancer." 
The first phase of the program will involve the establishment of an
NCCN Enzalutamide Request for Proposals Development Team to evaluate
existing data and to discuss and define the data and type of studies
necessary to further characterize the clinical effectiveness of
enzalutamide in bladder, breast, endometrial, hepatocellular,
ovarian, and prostate cancers. 
Enzalutamide is an androgen receptor inhibitor that acts on different
steps in the androgen receptor signaling pathway. Enzalutamide has
been shown to competitively inhibit androgen binding to androgen
receptors and inhibit androgen receptor nuclear translocation and
interaction with deoxyribonucleic acid (DNA).[i]  
The NCCN ORP draws on the expertise of investigators at NCCN Member
Institutions and the NCCN Affiliate Research Consortium (ARC) to
facilitate all phases of clinical research. This research is made
possible by collaborations with pharmaceutical and biotechnology
companies in order to advance therapeutic options for patients with
cancer. The NCCN ORP will utilize the grant from Astellas Pharma,
Inc. and Mediv
ation, Inc. to support investigator-initiated clinical
and correlative studies at NCCN Member Institutions and their
affiliate community hospitals for enzalutamide. To date, this
successful research model has received more than $44 million in
research grants and supported 116 studies that have produced a number
of publications in peer-reviewed journals. 
To learn more about the NCCN ORP and ongoing clinical trials, visit 
[i] U.S. Food and Drug Administration (FDA). Highlights of
prescribing information: 12: Clinical pharmacology: 12.1 Mechanism of
action. Available here:
/label/2012/203415lbl.pdf.Last accessed March 31, 2014.  
About the National Comprehensive Cancer Network 
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit
alliance of 25 of the world's leading cancer centers devoted to
patient care, research, and education, is dedicated to improving the
quality, effectiveness, and efficiency of cancer care so that
patients can live better lives. Through the leadership and expertise
of clinical professionals at NCCN Member Institutions, NCCN develops
resources that present valuable information to the numerous
stakeholders in the health care delivery system. As the arbiter of
high-quality cancer care, NCCN promotes the importance of continuous
quality improvement and recognizes the significance of creating
clinical practice guidelines appropriate for use by patients,
clinicians, and other health care decision-makers. 
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer
Center at The Nebraska Medical Center, Omaha, NE; City of Hope
Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and
Women's Cancer Center | Massachusetts General Hospital Cancer Center,
Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer
Center, Philadelphia, PA; Huntsman Cancer Institute at the University
of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert
H. Lurie Comprehensive Cancer Center of Northwestern University,
Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ,
Jacksonville, FL, and Rochester, MN; Memorial Sloan-Kettering Cancer
Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio
State University Comprehensive Cancer Center - James Cancer Hospital
and Solove Research Institute, Columbus, OH; Roswell Park Cancer
Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School of Medicine, St. Louis, MO;
St. Jude Children's Research Hospital/The University of Tennessee
Health Science Center, Memphis, TN; Stanford Cancer Institute,
Stanford, CA; University of Alabama at Birmingham Comprehensive
er Center, Birmingham, AL; UC San Diego Moores Cancer Center, La
Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San
Francisco, CA; University of Colorado Cancer Center, Aurora, CO;
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;
The University of Texas MD Anderson Cancer Center, Houston, TX;
Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer
Center/Smilow Cancer Hospital, New Haven, CT. 
Clinicians, visit Patients and caregivers, visit 
The following files are available for download: 

--  PDF

Katie Kiley Brown, NCCN
Press spacebar to pause and continue. Press esc to stop.